Long-term outcomes after recovery from TTP
| Outcome . | Comments . |
|---|---|
| Relapse | In patients with ADAMTS13 deficiency, the risk is estimated to be 41% at 7.5 years; the greatest risk is in the first year after recovery. Patients without ADAMTS13 deficiency rarely relapse.14 |
| Pregnancy complications | Women who have had TTP may have a higher risk for pregnancy-related complications. Recurrent TTP is uncommon with a subsequent pregnancy.58 |
| Other autoimmune disorders | Patients with acquired (autoimmune) ADAMTS13 deficiency may be at risk for developing other autoimmune disorders.36 |
| Minor cognitive abnormalities | Common; manifested by problems with memory, concentration, and fatigue.62 |
| Outcome . | Comments . |
|---|---|
| Relapse | In patients with ADAMTS13 deficiency, the risk is estimated to be 41% at 7.5 years; the greatest risk is in the first year after recovery. Patients without ADAMTS13 deficiency rarely relapse.14 |
| Pregnancy complications | Women who have had TTP may have a higher risk for pregnancy-related complications. Recurrent TTP is uncommon with a subsequent pregnancy.58 |
| Other autoimmune disorders | Patients with acquired (autoimmune) ADAMTS13 deficiency may be at risk for developing other autoimmune disorders.36 |
| Minor cognitive abnormalities | Common; manifested by problems with memory, concentration, and fatigue.62 |